Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | RGS12 | O14924 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19768940 | 0.78 | LMNA (0.41) | LMNAKMT2A | |
| SCHEMBL19490297 | 0.77 | SLC6A4 (0.39) | SLC6A4SLC6A3GPR84MAPTOPRM1 | |
| SCHEMBL30834353 | 0.74 | GPR84 (0.36) | SLC6A3GPR84MAPTLMNAOPRM1 | |
| SCHEMBL17479634 | 0.69 | ALDH1A1 (0.48) | SLC6A3MAPTLMNAMEN1KMT2A | |
| SCHEMBL30665115 | 0.68 | GPR84 (0.38) | SLC6A3GPR84MAPTLMNASPHK1 | |
| SCHEMBL18488029 | 0.67 | SYK (0.36) | KMT2A | |
| SCHEMBL19464655 | 0.66 | HSD17B10 (0.48) | MEN1APAF1RGS12HSP90AA1MAPK1 | |
| SCHEMBL20693674 | 0.66 | DPP4 (0.46) | LMNAKMT2A | |
| SCHEMBL5332047 | 0.64 | CYP3A4 (0.50) | SLC6A3TP53MAPTLMNAMEN1 | |
| Terephthalamide SCHEMBL8272704 | 0.63 | MAPK1 (0.51) | TP53S1PR2S1PR1MEN1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | SLC6A4 233/4885SLC6A3 489/4885GPR84 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.